PLEKHF2: Key Regulator of Cellular Processes and Potential Drug Target

Target Name: PLEKHF2

NCBI ID: G79666

PLEKHF2

PLEKHF2: Key Regulator of Cellular Processes and Potential Drug Target

Pleckstrin homology domain-containing family F member 2 (PLEKHF2) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the PLEKHF family, which is characterized by the presence of a PLEKHF2 gene in the genomic sequence.

The PLEKHF2 protein is known for its role in the regulation of various cellular processes, including cell adhesion, migration, and signaling pathways. It is a key regulator of theNotch signaling pathway, which is involved in the regulation of stem cell proliferation and the development of various tissues in the body.

Pleckstrin homology domain is a structural domain that is characterized by the presence of a specific arrangement of amino acids that is unique to the protein. This domain is named after the scientist who first identified it and is characterized by the presence of a specific conserved core and a variety of distinct amino acids.

One of the key functions of PLEKHF2 is its ability to interact with other proteins and molecules. This interaction occurs through the formation of a protein-protein interaction (PPI) complex, which is characterized by the presence of multiple distinct protein domains that interact with each other to promote the interaction between the proteins.

The PPI interaction between PLEKHF2 and its ligands is a critical regulatory mechanism that is involved in the regulation of various cellular processes. PLEKHF2 has been shown to interact with a variety of proteins, including the transcription factor, NF-kappa-B, and the protein, PDGF-尾.

In addition to its role in the regulation of cellular processes, PLEKHF2 is also a potential drug target. The PLEKHF2 gene has been shown to be involved in the regulation of various cellular processes, including the development of cancer.

Studies have shown that PLEKHF2 is highly expressed in various cancer tissues and that it is involved in the regulation of various cellular processes that are associated with cancer progression. In addition, PLEKHF2 has been shown to interact with the protein, PDGF-尾, which is a key regulator of cancer cell growth and survival.

The potential drug target for PLEKHF2 is the use of small molecules that can modulate its activity. This approach has been used to develop a variety of therapeutic compounds, including inhibitors of PDGF-尾, which have been shown to inhibit the growth and survival of cancer cells.

In conclusion, PLEKHF2 is a protein that is characterized by its ability to interact with other proteins and molecules and its role in the regulation of various cellular processes. Its potential as a drug target is due to its involvement in the regulation of cancer progression and its expression in various cancer tissues. Further research is needed to fully understand the role of PLEKHF2 in the development and progression of cancer.

Protein Name: Pleckstrin Homology And FYVE Domain Containing 2

Functions: May play a role in early endosome fusion upstream of RAB5, hence regulating receptor trafficking and fluid-phase transport. Enhances cellular sensitivity to TNF-induced apoptosis (PubMed:18288467)

The "PLEKHF2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLEKHF2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets